Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 167
- Registration Number
- NCT02564770
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 63
- Registration Number
- NCT02565641
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02564107
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 54
- Registration Number
- NCT02564094
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT02563054
A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1035
- Registration Number
- NCT02560974
A Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in Healthy Participants
Completed
- Conditions
- Healthy Volunteer
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02560142
- Locations
- 🇳🇱
PRA Health Sciences Early Development Services, Zuidlaren, Netherlands
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT02561039
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Biological: RO6874813
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT02558140
- Locations
- 🇺🇸
SCRI, Nashville, Tennessee, United States
🇪🇸Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
🇪🇸START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2a
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 697
- Registration Number
- NCT02557646
© Copyright 2025. All Rights Reserved by MedPath